Clavulanic Acid: A Novel Potential Agent in Prevention and Treatment of Scopolamine-Induced Alzheimer’s Disease
Mahdieh Anoush, Zeinab Pourmansouri, Rafi Javadi, Benyamin GhorbanPour, Ali Sharafi, Hamed Mohamadpour, Iraj Jafari Anarkooli, Sina Andalib
Abstract
: The results show that the administration of clavulanic acid before and after the use of scopolamine can reduce the percentage of apoptotic cells in the hippocampus and also improve the parameters related to learning and spatial memory; however, its effect in the prophylactic state was stronger. The results obtained from memantine revealed that it has neuroprotective potency against AD; however, clavulanic acid had a greater effect. Also, with increased expression of the neuroprotective genes, clavulanic acid could be considered as an option in the upcoming preclinical and clinical research about Alzheimer's disease.